Psilocybin-Assisted Therapy Achieves Positive Clinical Trial Results For Treating Generalized Anxiety
Psilocybin-assisted therapy has hit a milestone as clinical trial results show potential benefits for Generalized Anxiety Disorder (GAD.)
With variable symptoms, the condition typically involves a person suffering from excessive anxiety and worry for over six months, potentially causing significant distress and impairment in social, occupational or other areas of functioning. A relatively common disorder, successful treatment of GAD remains inadequate, bringing on side effects and high costs.
The new topline clinical outcomes correspond to a Phase 2 study assessing psilocybin therapy’s potential for treatment of Generalized Anxiety Disorder (GAD), conducted by clinical-stage cannabinoid and psychedelics biotech company Incannex Healthcare IXHL. Read more.
Beckley Academy’s Open-Source Psychedelic Therapy Learning Framework Is Out: What’s It All About? Authoring Team Shares Insights
The medical psychedelics field is at a pivotal juncture. With MDMA-assisted therapy close to federal legalization for the treatment of PTSD in the U.S. and other psychedelic substances potentially following suit, these therapies are poised to revolutionize treatment for certain mental health issues.
And yet the field has some recognizable and potentially conflictive gaps, such as the absence of national training standards and certifications for those providing the therapies.
To remedy this lack, the educational studio Beckley Academy is moving forward by publishing what’s believed to be the first open-source learning framework to advance psychedelic-assisted therapy (PAT) training standards. Learn more.
EXCLUSIVE: Enveric Biosciences Announces Non-Binding Deals To License Three Types Of Drug Compounds
Enveric Biosciences ENVB, a Florida-headquartered biotech company developing novel neuroplasticity-promoting small molecule therapeutics for depression, anxiety and addiction disorders treatment has signed three non-binding term sheets with another (undisclosed) biotechnology company toward the out-licensing of three classes of compounds.
The news comes shortly after the company announced the sale of its cancer patents, to further its path to mental health treatment development.
The three term sheets contemplate that the undisclosed licensee would receive exclusive, royalty-bearing global licenses to develop and sublicense the assets, along with cash buyout options and future option rights to substantially related assets in the Enveric portfolio. The licensee would assume responsibility for all future preclinical and clinical development for all human and/or animal pharmaceutical applications. Keep reading.
The Milestone Round
- Compass Pathways CMPS shows robust 2023 year-end results, embraces clinical milestones for psilocybin as depression treatment.
- GH Research GHRS: European biotech reports full-year 2023 financial results and business updates.
- MindMed’s MNMD 2023 financial results and business recap: Milestones amid rising expenses.
- What’s going on with Incannex stock? (Feb. 28)
- Cybin Inc. CYBN Q3 earnings: Clinical advances amid financial loss.
- Psychedelics reform update: Connecticut’s decriminalization, Vermont hearings, Arizona’s psilocybin services & more.
- Podcast – Post-frenzy psychedelics investing and reclaiming the right to pursue happiness with Zappy Zapolin: ‘2024 is when it goes mainstream.’
- Cannabis industry veteran on market trends, DEA rescheduling, THC types, psychedelics and more.
- Too drunk? FSD Pharma's HUGE new beverage could sober you up quickly.
- LSD microdosing for depression? MindBio's clinical study revealed promising results.
- EXCLUSIVE: Psychedelic-focused firm Clearmind Medicine CMND submitted three new international patent applications for MDMA, ibogaine and ketamine compounds. The news follows other three filed patents together with partner SciSparc SPRC.
- Red Light Holland TRUFF exports psilocybin for research, microdosing capsules in development, and more news from the Canadian company.
- Medford Massachusetts move to decriminalize psychedelics has statewide reform implications.
- Washington doctor vs. DEA for lawful use of psilocybin to treat terminally ill patients.
- Paramedic sentenced to 5 years in ketamine death of Elijah McClain, judge says ‘It is impossible to unremember’ video of his suffering.
- Meet Oregon’s legal psilocybin retreats powered by NASA and Ivy League talent.
- ‘You need a little peyote’: Jane Fonda and Lily Tomlin’s advice for Stephen Colbert.
- Why people get hand cramps when taking psychedelics and how to prevent them.
See Also: Last Week’s Edition Of ‘Psyched’
Psychedelics ETF's Weekly Performance
AdvisorShares Psychedelics ETF PSIL opened Monday, March 4 at $1.58, following prior openings at $1.46, $1.47 and $1.44 (Feb. 26, 20 and 12, respectively.)
On Friday, March 1 it closed at $1.57, following prior closings at $1.41, $1.46 and $1.44, (Feb. 23, 16 and 9, respectively.)
Last week's highest was closing price $1.57, vs. prior weekly highests at $1.52, $1.50 and $1.50.
Week's lowest was $1.43, vs. prior weekly lowests at $1.41, $1.40 and $1.37.
Highest Trading Psychedelics Stocks Friday, March 1 At Close
- COMPASS Pathways closed at $11.47, up from prior closings at $10.20, $10.50 and $10.35 (Feb. 23, 16 and 9, respectively.)
- GH Research closed at $8.50, up from prior closings at $7.51, $8.00 and $8.06.
- Mind Medicine (MindMed) closed at $6.21, sustaining the upstream as per prior closings at $4.91, $4.93 and $4.41.
- Incannex Healthcare closed at $5.37, also up as per prior closings at $4.84, $4.70 and $3.24.
- Atai Life Sciences ATAI closed at $2.14, also up from prior closings at $1.83, $1.84 and $1.73.
- Lucy Scientific LSDI closed at $1.91, dropping as per prior closings at $2.42, $2.01 and $2.60, yet back again in the top 10 highest-trading psychedelic stocks.
- Bright Minds Biosciences DRUG closed at $1.76, slightly behind prior closings at $1.88, $1.95 and $1.95.
- Clearmind Medicine closed at $1.60, following prior closings at $1.81, 1.29 and $1.42.
- Silo Pharma SILO closed at $1.59, closely following prior closings at $1.57, $1.55 and $1.52.
- Enveric Biosciences closed at $1.62, jumping from prior closings at $0.95, $0.83 and $0.76.
Stock trading numbers above according to Benzinga Pro, our all-the-information-you-need streaming platform helping you invest smarter – Come join us and see for yourself!
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis rescheduling seems to be right around the corner
Want to understand what this means for the future of the industry? Hear directly for top executives, investors and policymakers at the 19th Benzinga Cannabis Capital Conference, coming to Chicago this Oct. 8-9. Get your tickets now before prices surge by following this link.